First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at least 50%. However, little is known about the value of adding chemotherapy to pembrolizumab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yixin, Lin, Zuan, Zhang, Xuanye, Chen, Chen, Zhao, Hongyun, Hong, Shaodong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500047/
https://www.ncbi.nlm.nih.gov/pubmed/31053172
http://dx.doi.org/10.1186/s40425-019-0600-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500047/
https://www.ncbi.nlm.nih.gov/pubmed/31053172
http://dx.doi.org/10.1186/s40425-019-0600-6

Ejemplares similares